ClinicalTrials.Veeva
Menu

Find clinical trials for COVID-19 in Hanyang, Seoul

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Infections
Coronavirus Infections
Human Influenza
Communicable Diseases
Post-Acute COVID-19 Syndrome
Syndrome
Pneumonia

COVID-19 trials near Hanyang, Seoul, KOR:

Immunogenicity and Safety of AdCLD-CoV19-1 OMI As a Booster: a COVID-19 Preventive Vaccine in Healthy Volunteers (COVID-19)

The immunogenicity and safety of AdCLD-CoV19-1 OMI (5.0x10\^10 VP (0.5 mL)/dose/Vial) administered as a booster in healthy adults aged 19 years old a...

Active, not recruiting
COVID-19
Vaccines
Biological: Comirnaty Bivalent 0.1mg/mL (tozinameran and riltozinameran)
Biological: AdCLD-CoV19-1 OMI

Phase 3

Cellid

Seoul, Korea, Republic of and 16 other locations

Efficacy and Safety of ES16001 in Patients With COVID-19

legal age for adult in each country) with confirmed mild or moderate COVID-19 tested positive with a real time reverse transcriptio...

Enrolling
COVID-19
Drug: ES16001 80 mg
Drug: ES16001 40 mg

Phase 2, Phase 3

Genencell

Seoul, Korea, Republic of and 2 other locations

Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study

known SARS-CoV-2 variants of concern for pre-exposure prophylaxis of COVID-19.The aim of the Phase I/III study (Parent Study) will -...

Active, not recruiting
COVID-19, SARS-CoV-2
Biological: AZD3152 (Sub-study)
Biological: Placebo (Parent study Sentinel Safety Cohort)

Phase 2, Phase 3

AstraZeneca
AstraZeneca

Seoul, Korea, Republic of and 214 other locations

Phase 2b/3 Trial of NuSepin® in COVID-19 Pneumonia Patients

Parallel-treatment Group, Adaptive Design, Multi-center, Phase 2b/3 Trial to Evaluate Efficacy and Safety of NuSepin® Intravenous Infusion in COVID...

Enrolling
COVID-19 Pneumonia
Drug: Placebo
Drug: NuSepin® 0.2 mg/kg

Phase 2, Phase 3

Shaperon

Incheon, Namdong-gu, Korea, Republic of

Locations recently updated

Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

seek to enroll immunocompromised patients with Lower Tract parainfluenza infection.It also contains a sub-study to enroll patients with severe COVID...

Enrolling
COVID-19
Parainfluenza
Drug: DAS181 COVID-19
Drug: DAS181

Phase 3

Ansun Biopharma

Seoul, Gyeonggi-do, Korea, Republic of and 66 other locations

New

Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age

The purpose the study is to evaluate the immunogenicity, reactogenicity, and safety of mRNA-1083 in adults 50 years of age and older in participating...

Not yet enrolling
COVID-19
Influenza
Biological: Licensed Influenza Vaccine
Biological: mRNA-1083

Phase 3

Moderna
Moderna

Seoul, Korea, Republic of and 42 other locations

GLS-5310 Vaccine for the Prevention of SARS-CoV-2 (COVID-19)

This clinical trial will evaluate the safety, tolerability and immunogenicity of GLS-5310 DNA vaccine against SARS-CoV-2(COVID-19) ...

Active, not recruiting
SARS-CoV-2
Biological: GLS-5310
Biological: Placebo

Phase 1, Phase 2

GeneOne Life Science

Seoul, Korea, Republic of

GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19)

This clinical trial will evaluate the safety, tolerability and efficacy of GLS-1027 in the prevention of severe pneumonitis caused by SARS-CoV-2 infe...

Active, not recruiting
Pneumonitis
SARS-CoV Infection
Drug: GLS-1027
Drug: Placebo

Phase 2

GeneOne Life Science

Seoul, Korea, Republic of and 16 other locations

Study to Assess Safety, Reactogenicity and Immunogenicity of the repRNA(QTP104) Vaccine Against SARS-CoV-2(COVID-19)

This study is to evaluate the safety, reactogenicity, and immunogenicity of the QTP104 vaccine against SARS-CoV-2 infection in healthy adults.

Active, not recruiting
COVID-19
SARS-CoV-2
Biological: QTP104 1ug
Biological: QTP104 5ug

Phase 1

Quratis

Seoul, Korea, Republic of and 1 other location

Evaluation of Safety and Immunogenicity of a SARS-CoV-2(Severe Acute Respiratory Syndrome Coronavirus 2) Booster Vaccine (LEM-mR203)

A dose-escalation, double-blinded, randomized, placebo-controlled phase 1 study to assess the safety, reactogenicity, and immunogenicity of a SARS-Co...

Enrolling
COVID-19 Vaccine Adverse Reaction
COVID-19 Infection
Biological: Placebo
Biological: LEM-mR203

Phase 1

Lemonex

Seoul, Korea, Republic of

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems